What are the recommended antipseudomonal antibiotic options and adult dosing regimens?

Antipseudomonal Antibiotics: Recommended Options and Adult Dosing

For empiric antipseudomonal coverage in adults, use a β-lactam agent as the backbone: piperacillin-tazobactam 4.5 g IV q6h, cefepime 2 g IV q8h, ceftazidime 2 g IV q8h, meropenem 1 g IV q8h, or imipenem 500 mg IV q6h. 1

β-Lactam-Based Agents (Primary Options)

These are your first-line antipseudomonal agents:

Antipseudomonal Penicillins:

• Piperacillin-tazobactam: 4.5 g IV q6h 1, 2
  • For documented Pseudomonas aeruginosa, may increase to 3.375 g q4h or 4.5 g q6h 2
  • Consider extended infusions for pharmacodynamic optimization 1

Antipseudomonal Cephalosporins:

• Cefepime: 2 g IV q8h 1, 2
• Ceftazidime: 2 g IV q8h 1, 2
  • Both achieve optimal pharmacodynamic targets with standard dosing 3

Carbapenems:

• Meropenem: 1 g IV q8h 1, 2
• Imipenem: 500 mg IV q6h 1, 2
  • Lower dose in patients <70 kg to prevent seizures 1
• Doripenem: 500 mg IV q8h 2

Monobactam:

• Aztreonam: 2 g IV q8h 1, 2
  • Can be combined with another β-lactam (different cell wall targets) 1
  • Useful in severe penicillin allergy 1

Non-β-Lactam Agents (Adjunctive/Alternative Options)

Fluoroquinolones:

• Ciprofloxacin: 400 mg IV q8h 1, 2
• Levofloxacin: 750 mg IV q24h 2

Aminoglycosides:

• Amikacin: 15-20 mg/kg IV q24h 1, 2
• Gentamicin: 5-7 mg/kg IV q24h 1, 2
• Tobramycin: 5-7 mg/kg IV q24h 1, 2
  • Critical caveat: Never use aminoglycosides as sole antipseudomonal agent 1
  • Require drug level monitoring and dose adjustment 1
  • Associated with lower clinical response rates on meta-analysis 1

Polymyxins (Reserve Agents):

• Colistin: 5 mg/kg IV × 1 loading dose, then 2.5 mg × (1.5 × CrCl + 30) IV q12h 1
• Polymyxin B: 2.5-3.0 mg/kg/day divided q12h 1
  • Reserve for high MDR prevalence settings with local expertise 1

When to Use Double Antipseudomonal Coverage

Use two agents from different classes when:

• Prior IV antibiotic use within 90 days 1
• Septic shock at time of VAP 1
• ARDS preceding VAP 1
• ≥5 days hospitalization before VAP 1
• Acute renal replacement therapy before VAP 1
• Structural lung disease (bronchiectasis, cystic fibrosis) 1
• High mortality risk (ventilatory support, septic shock) 1

Combination strategy: Select one β-lactam (Column B) + one non-β-lactam agent (Column C) - avoid combining two β-lactams except aztreonam 1

Key Pharmacodynamic Considerations

Extended infusions improve outcomes for time-dependent β-lactams, particularly in late-onset or severe infections 1, 3:

• Cefepime, ceftazidime, meropenem: Consider 3-hour infusions for optimal target attainment 3
• Piperacillin-tazobactam: Extended infusion appropriate 1

Dosing must be optimized: Guideline-discordant dosing significantly increases treatment failure (62% vs 48%, p=0.04) 4. Supratherapeutic dosing based on disease severity, renal function, and patient-specific factors is essential.

Critical Pitfalls to Avoid

1. Never use aminoglycosides alone for antipseudomonal coverage - they have inferior clinical response rates and should only be used in combination 1

2. Adjust all doses for renal/hepatic dysfunction - the doses listed assume normal organ function 1

3. Imipenem seizure risk: Reduce dose in patients <70 kg 1

4. Polymyxins are last resort only - use only when high MDR prevalence and institutional expertise available 1

5. Tailor to local antibiogram - empiric regimens must be informed by institutional susceptibility patterns 1

6. Consider extended infusions - particularly for cephalosporins and carbapenems in severe infections to maximize time above MIC 1, 3